NCT05136846View on ClinicalTrials.gov

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Locally Advanced Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Unresectable Lung Non-Small Cell Carcinoma
Interventions
DRUG

Carboplatin

Given IV

BIOLOGICAL

Durvalumab

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Papaverine

Given IV or SC

RADIATION

Radiation Therapy

Undergo RT

DRUG

Pemetrexed

Given IV

RADIATION

Hypofractionated Radiation Therapy

Undergo hypofractionated RT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Computed Tomography

Undergo PET/CT or CT

PROCEDURE

Magnetic Resonance Imaging of the Brain with and without Contrast

Undergo brain MRI

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (2)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

91010

RECRUITING

City of Hope, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Ohio State University Comprehensive Cancer Center

OTHER